secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001645113-23-000006
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novocure reports preliminary FY2022 net revenue $537.8M (+1% YoY); LUNAR study meets primary endpoint
--------------------------------------------------------------------------------

- FY2022 net revenue $537.8M, +1% YoY; Q4 net revenue $128.4M, with US $98.6M, EMEA $17.0M, Japan $7.9M, Greater China $4.9M.
- Cash, equivalents and short-term investments $969.4M as of Dec 31, 2022.
- 3,430 active patients; 1,373 prescriptions received in Q4 (North America 956, EMEA 312, Japan 105).
- LUNAR study met primary endpoint: significant overall survival benefit with TTFields + immune checkpoint inhibitors in NSCLC.
- New thinner/lighter arrays launched in Europe under limited market release; Health Canada approved Optune for GBM.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511323000006/0001645113-23-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511323000006/nvcr-20230109.htm
  HTML page:      https://secwatch.observer/filing/0001645113-23-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer